Drug rediscovery in gastroenterology: From off-label to on-label use of thioguanine in inflammatory bowel disease

Nanne K. H. de Boer, Melek Simsek, Berrie Meijer, Markus F. Neurath, Ad. van Bodegraven, Chris J. J. Mulder

Research output: Contribution to journalReview articleAcademicpeer-review

2 Citations (Scopus)

Abstract

Drug rediscovery refers to the principle of using € old' drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. In this paper, we aim to visualise potential hurdles that hamper drug rediscovery in general, emphasise the global need for optimal use and development of potentially useful drugs, and provide an overview of the registration process for TG in the Netherlands. With this summary, we aim to guide drug rediscovery trajectories in the near future.
Original languageEnglish
Article numbergutjnl-2023-329679
Pages (from-to)1985-1991
Number of pages7
JournalGut
Volume72
Issue number10
Early online date2023
DOIs
Publication statusPublished - 1 Oct 2023

Keywords

  • azathioprine
  • crohn's disease
  • drug development
  • drug metabolism
  • inflammatory bowel disease

Cite this